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The treatment of kidney cancer has made some remark-
able strides over the last few years. Two regimens received 
Food and Drug Administration (FDA) approval, multiple 
biomarkers were reported to show promise, and further en-
hancement and refinement of the prognostic characteristics 
occurred. The combinations of anti-angiogenic tyrosine ki-
nase inhibitors with immune checkpoint inhibitors have rap-
idly become the preferred therapies in the front-line setting of 
advanced renal cancer. 
The combinations of axitinib with either avelumab or pem-
brolizumab have received FDA approval in all risk groups of 
advanced renal cancer. In the backdrop of immune check-
point combination therapy of ipilimumab and nivolumab 
being approved for intermediate and poor-risk RCC, three 
options of therapy for the initial management of advanced 
renal cancer have been proposed. Multiple other trials of 
combinations of cabozantinib and nivolumab, and lenvatinib 
and pembrolizumab, and triplet regimens, involving cabozan-
tinib and ipilimumab and nivolumab, are likely to continue to 
revolutionize the landscape of RCC therapeutics. Recently, 
the 42-month overall survival was reported for the Check-
Mate 214 trial, with the long-term remission results being 
upheld. 
Renal Cancer therapeutics has come a long way from 
witnessing nephrectomy make a small survival benefit or 
waiting for interleukin 2 to show a response in a chosen 
few, to doubling of  median survival within the clinical trial 
patient population. We have gradually been able to impact 
specific subtypes, such as sarcomatoid RCC, but remain far 
behind in customizing therapies to the individual patient. 
The expansion into the area of  combinations of  local ther-
apies and synergy with systemic therapies has added a new 
dimension to the management of  oligometastatic disease. 
These approaches are very expensive and not without tox-
icities—both acute and chronic—and are currently lacking 
randomized evidence. In select patients, the results appear 
promising, but real-world vetting is required. In compar-
ison with systemic therapy alone, the incremental benefit 
was disappointingly small. 
Every patient is a complex clinical trial,  
with N = 1
The future will bring profiling of  each patient to deter-
mine therapy; however, specific biomarkers guiding ther-
apy remain elusive. Currently, in RCC, biomarkers have 
shown their utility in predicting prognosis alone but not 
in guiding therapies. The year 2020 will likely bring mul-
tiple therapeutic regimens, such as lenvatinib and pem-
brolizumab and cabozantinib and nivolumab, which will 
represent therapeutic advances. S1500, the papillary renal 
cancer study, will likely establish a baseline therapy and 
clinical outcome in this rare disease for future clinical trial 
development. Along with this comes the responsibility 
of  clinical application of  results to the community and 
real-world population. Systemic therapy should be the 
mainstay of  management in metastatic RCC, and the role 
of  cytoreductive nephrectomy should be carefully consid-
ered. The next randomized trial will address the compar-
ison of  deferred cytoreductive nephrectomy and whether 
that has a survival impact on the control arm of  systemic 
therapy alone. 
The sobering truth is that in spite of exciting advances, we 
are not currently curing more than half  of the kidney cancer 
patients. A well-known adage states, “Celebrate your suc-
cesses and learn from our failures.” However, in the era of 
genomics, we cannot just rest on our laurels but need to learn 
even more from our successes to help streamline therapies 
for future patients. The microbiome studies are an example 
of how the responding patients can help contribute to im-
prove outcomes in others less fortunate. We should continue 
the teamwork between patient advocates and basic science 
researchers and clinicians toward the mission of beating kid-
ney cancer. 
For the last 2 years, Nobel prizes in medicine have made 
a deep impact on kidney cancer management. Both the im-
mune checkpoint and the hypoxia inducible factor pathways 
reflect the pathophysiology of the majority of clear cell RCC 
and have been harnessed for therapeutic purposes. Specific 
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populations, such as patients with synchronous metastatic 
disease, patients with autoimmune diseases, renal transplant 
patients, dialysis patients, and patients presenting with lo-
coregionally advanced disease, have been underrepresented 
in clinical trials, and further studies focusing on them are 
required. Future challenges lie in optimizing current thera-
pies and identifying novel targets and therapies to improve 
outcomes. 
